Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Panobinostat - Novartis/Secura Bio

Drug Profile

Panobinostat - Novartis/Secura Bio

Alternative Names: Faridak; Farydak; LBH-589; LBH-589A

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Georgia Regents University; H. Lee Moffitt Cancer Center and Research Institute; HOVON Foundation; Icahn School of Medicine at Mount Sinai; Mayo Clinic; National Cancer Institute (USA); New York University School of Medicine; Novartis; Peter MacCallum Cancer Centre; St. Jude Childrens Research Hospital; Therapeutic Advances in Childhood Leukemia & Lymphoma; Thomas Jefferson University; University of Aarhus; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Hydroxamic acids; Indoles; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II/III Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Graft-versus-host disease; Lymphoma; Myelodysplastic syndromes; Myelofibrosis; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Renal cell carcinoma; Thyroid cancer; Waldenstrom's macroglobulinaemia
  • Phase I/II Breast cancer; HIV-1 infections; Hodgkin's disease; Malignant melanoma
  • No development reported Brain metastases; CNS cancer; Gastrointestinal stromal tumours; Glioma; Head and neck cancer; Mantle-cell lymphoma; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer; Solid tumours
  • Discontinued Cutaneous T-cell lymphoma; Prostate cancer

Most Recent Events

  • 09 Jul 2019 Launched for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Finland, Denmark, Ireland, United Kingdom, Czech Republic, Netherlands, Norway, Japan, Belgium, Poland, Australia and Greece (PO)
  • 14 Jun 2019 Novartis plans a phase Ib trial for Melanoma and Non small cell lung cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) (NCT03982134)
  • 28 May 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, First-line therapy, In the elderly, In adults) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top